Overall | Untreated | Treated | P-value | |
---|---|---|---|---|
DIC score ≥ 4 and PT-INR ≥ 1.3 | n = 295 | n = 139 | n = 156 | |
SOFA score 0 h | 11 (8–13) | 11 (7–12) | 11 (8–13) | 0.078 |
APACHE II score | 25 (19–32) | 23 (17–29) | 27 (20–34) | 0.003 |
In-hospital mortality, % (freq.) | 28.5% (84) | 26.6% (37) | 29.7% (47) | 0.505 |
DIC score ≥ 4 and PT-INR ≥ 1.4 | n = 215 | n = 99 | n = 116 | |
SOFA score 0 h | 11 (8–13) | 11 (7–12) | 11 (8–13) | 0.219 |
APACHE II score | 26 (20–33) | 26 (17–29) | 27 (21–34) | 0.108 |
In-hospital mortality, % (freq.) | 32.6% (70) | 31.3% (31) | 33.6% (39) | 0.719 |
DIC score ≥ 4 and PT-INR ≥ 1.5 | n = 143 | n = 62 | n = 81 | |
SOFA score 0 h | 12 (9–14) | 12 (10–14) | 11 (7–13) | 0.829 |
APACHE II score | 26 (20–33) | 26 (19–31) | 25 (19–33) | 0.961 |
In-hospital mortality, % (freq.) | 35.7% (51) | 41.9% (26) | 30.9% (25) | 0.171 |
DIC score ≥ 4 and PT-INR ≥ 1.6 | n = 109 | n = 49 | n = 60 | |
SOFA score 0 h | 12 (9–14) | 12 (9–13) | 11 (8–14) | 0.904 |
APACHE II score | 26 (20–33) | 26 (18–30) | 27 (21–33) | 0.943 |
In-hospital mortality, % (freq.) | 42.2% (46) | 46.9% (23) | 38.3% (23) | 0.366 |
DIC score ≥ 5 and PT-INR ≥ 1.3 | n = 233 | n = 102 | n = 131 | |
SOFA score 0 h | 11 (8–13) | 11 (7–13) | 11 (8–13) | 0.581 |
APACHE II score | 26 (19–33) | 26 (17–29) | 26 (20–34) | 0.136 |
In-hospital mortality, % (freq.) | 31.3% (73) | 31.4% (32) | 31.3% (41) | 0.990 |
DIC score ≥ 5 and PT-INR ≥ 1.4 | n = 177 | n = 76 | n = 101 | |
SOFA score 0 h | 11 (9–14) | 11 (7–12) | 11 (8–13) | 0.667 |
APACHE II score | 26 (20–33) | 26 (17–29) | 27 (21–34) | 0.431 |
In-hospital mortality, % (freq.) | 35.0% (62) | 35.5% (27) | 34.5% (35) | 0.904 |
DIC score ≥ 5 and PT-INR ≥ 1.5 | n = 121 | n = 49 | n = 72 | |
SOFA score 0 h | 12 (9–14) | 12 (11–14) | 11 (8–13) | 0.480 |
APACHE II score | 26 (21–33) | 28 (21–33) | 26 (20–33) | 0.616 |
In-hospital mortality, % (freq.) | 37.2% (45) | 46.9% (23) | 30.6% (22) | 0.067 |
DIC score ≥ 5 and PT-INR ≥ 1.6 | n = 92 | n = 38 | n = 54 | |
SOFA score 0 h | 12 (9–14) | 12 (9–14) | 11 (10–13) | 0.533 |
APACHE II score | 27 (22–33) | 26 (18–32) | 28 (22–33) | 0.474 |
In-hospital mortality, % (freq.) | 43.5% (40) | 52.6% (20) | 37.0% (20) | 0.137 |
DIC score ≥ 6 and PT-INR ≥ 1.3 | n = 140 | n = 58 | n = 82 | |
SOFA score 0 h | 12 (9–14) | 11 (7–14) | 12 (9–14) | 0.970 |
APACHE II score | 28 (20–34) | 25 (17–31) | 29 (22–35) | 0.239 |
In-hospital mortality, % (freq.) | 31.4% (44) | 34.5% (20) | 29.3% (24) | 0.513 |
DIC score ≥ 6 and PT-INR ≥ 1.4 | n = 109 | n = 45 | n = 64 | |
SOFA score 0 h | 12 (9–14) | 10 (7–14) | 12 (9–14) | 0.712 |
APACHE II score | 27 (20–33) | 21 (15–30) | 29 (23–34) | 0.332 |
In-hospital mortality, % (freq.) | 32.1% (35) | 37.8% (17) | 28.1% (18) | 0.288 |
DIC score ≥ 6 and PT-INR ≥ 1.5 | n = 76 | n = 30 | n = 46 | |
SOFA score 0 h | 13 (10–14) | 13 (10–14) | 12 (10–14) | 0.239 |
APACHE II score | 28 (22–33) | 29 (20–33) | 29 (22–33) | 0.601 |
In-hospital mortality, % (freq.) | 32.9% (25) | 50.0% (15) | 21.7% (10) | 0.010 |
DIC score ≥ 6 and PT-INR ≥ 1.6 | n = 61 | n = 25 | n = 36 | |
SOFA score 0 h | 12 (9–14) | 11 (9–14) | 12 (9–14) | 0.195 |
APACHE II score | 28 (22–33) | 28 (18–32) | 27 (21–33) | 0.154 |
In-hospital mortality, % (freq.) | 41.0% (25) | 56.0% (14) | 25.0% (9) | 0.014 |